Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

Volume last week, and since mid-December spiked considerably.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jfk Member Profile
 
Followed By 2
Posts 210
Boards Moderated 0
Alias Born 05/10/07
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/11/2019 5:03:07 PM
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting GlobeNewswire Inc. - 5/31/2019 1:00:00 AM
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study GlobeNewswire Inc. - 5/30/2019 1:00:00 AM
BrainStorm Senior Management to Present at BIO 2019 GlobeNewswire Inc. - 5/28/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2019 8:01:41 AM
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London GlobeNewswire Inc. - 5/13/2019 1:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:03:29 PM
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update GlobeNewswire Inc. - 5/10/2019 5:00:00 PM
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases GlobeNewswire Inc. - 4/30/2019 4:00:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/1/2019 3:35:52 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2019 5:08:02 PM
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting GlobeNewswire Inc. - 3/28/2019 4:30:00 AM
BrainStorm Announces Grant of an additional New European Patent for NurOwn® GlobeNewswire Inc. - 3/26/2019 6:30:00 AM
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS GlobeNewswire Inc. - 3/14/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2019 6:13:38 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/8/2019 5:05:02 PM
BrainStorm to Host Business Update Conference Call GlobeNewswire Inc. - 3/7/2019 4:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/22/2019 5:03:13 PM
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study GlobeNewswire Inc. - 2/22/2019 7:30:00 AM
BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland GlobeNewswire Inc. - 2/21/2019 6:00:00 AM
BrainStorm Issues a Statement to Patients and Shareholders GlobeNewswire Inc. - 2/19/2019 8:06:49 AM
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposiu... GlobeNewswire Inc. - 2/4/2019 8:22:51 AM
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida GlobeNewswire Inc. - 1/25/2019 7:15:00 AM
BrainStorm Granted Additional Patent for NurOwn® in Israel GlobeNewswire Inc. - 1/22/2019 8:40:00 AM
jfk   Saturday, 01/12/19 09:35:42 PM
Re: condoe3 post# 2474
Post # of 2517 
Volume last week, and since mid-December spiked considerably. Appears that institution(s) are taking an interest here. Don't believe that they are giving up anything this early in the game. Chaim is willing to assume more risk here, but perhaps he's getting funding to do the MS work and that is becoming known, OR they have another indication that they will soon announce. They are clearly getting additional backing as their science gets moved further downfield and is proving itself. Its going to get stronger respect/higher share price over the next 12 months.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist